Clinical Trial Update: Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating the selective p38 MAPK alpha inhibitor neflamapimod in adults with mild Alzheimer's disease has been completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• nefla mapimod (neflamapimod)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-10-27